Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Aptevo Therapeutics
Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)